

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): **Michael W. Miller** : Group Art Unit: **To be assigned**
Serial No.: **To be assigned** : Examiner: **To be assigned**
Filed: **To be assigned** :
For: **CCR5 Antagonists Useful
For Treating AIDS** : Attorney Docket No. : **IN01415K1B**

X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references are attached were filed in related application U.S. Serial No(s) 10/107,940 filed March 27, 2002, respectively.

(b) No fee is believed due because:

- This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- This Information Disclosure Statement is being concurrently filed with the above-identified application.
- This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) This Information Disclosure Statement is being filed on or before the payment of the issue fee; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and


The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **19-0365**, Patent Case No. **IN01415K1B**. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION

Dated: **February 6, 2004**
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By:


Name: **Anita W. Magatti**
Reg. No.: **29.825**
Attorney of Record
Telephone No.: (908) 298-5067

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: IN01415K1B	SERIAL NO.: To be assigned
				APPLICANT: Michael W. Miller	
				FILING DATE: To be assigned	GROUP: To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	5,883,096	3/16/99	Lowe et al	514		
	AB	5,889,006	3/30/99	Lowe et al	519		
	AC	6,037,352	3/14/00	Lowe et al	514		
	AD	5,952,349	9/14/99	Asberom et al	514		
	AE	5,977,138	11/2/99	Wang et al	514		
	AF	6,066,636	5/23/00	Kozlowski et al	514		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	AL	WO 00/66559	11/9/00	WIPO			
	AM	WO 00/66558	11/9/00	WIPO			
	AN	WO 99/04794	2/4/99	WIPO			
	AO	WO 97/24324	7/10/97	WIPO			
	AP	WO 97/16440	5/9/97	WIPO			
	BL	WO 94/18192	8/18/94	WIPO			
	BM	1 103 276	6/28/00	Europe			

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AQ	Vandamme et al, <u>Antiviral Chemistry and Chemotherapy</u> , <u>9</u> (1998) p. 187-203
AR	Connor et al, <u>Virology</u> , <u>206</u> (1995) p. 935-944
AS	Plater-Zyberk et al, <u>Immunol. Lett.</u> , <u>57</u> (1997) p. 117-120
AT	Boiardi et al, <u>Clinical and Experimental Rheumatology</u> , <u>17</u> , (1999) p. 419-425
AU	Hatano et al, <u>Clin. Exp. Immunol.</u> , <u>117</u> (1999) p. 237-243
AV	Raychaudhuri et al, <u>International J. of Immunopharmacology</u> , <u>20</u> (1998) p. 661-667
AW	Chihara et al, <u>J. Allergy Clin. Immunol.</u> , <u>100</u> , 6, part 2 (1997) p. S52-S55
AX	Beck et al, <u>J. Immunol.</u> , <u>159</u> , 6 (1997) p. 2962-72
AY	Tagat et al, <u>Bioorganic & Medicinal Chemistry Letters</u> , <u>11</u> (2001) 2143-2146.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.